Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies

Journal of Infectious Diseases

Volumn 212, Issue 7, 2015, Pages 1111-1119

  Espinosa, Diego A ^a   Gutierrez, Gabriel M ^b   Rojas Lopez, Maricarmen ^a   Noe, Amy R ^b   Shi, Lirong ^a   Tse, Sze Wah ^a,c   Sinnis, Photini ^a   Zavala, Fidel ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antibodies; CSP; malaria; P. falciparum; sporozoites; vaccine

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2A10; MONOCLONAL ANTIBODY 5D5; UNCLASSIFIED DRUG; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; EPITOPE; MALARIA VACCINE; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADOPTIVE TRANSFER; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; LIVER CELL; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTECTION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SPOROZOITE; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; HUMAN; IMMUNOLOGY; MALARIA, FALCIPARUM; MALE; MOUSE; PARASITOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, PROTOZOAN; ANTIBODY SPECIFICITY; EPITOPES; FEMALE; HEPATOCYTES; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MICE; MICE, INBRED C57BL; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SPOROZOITES;

EID: 84936978099     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv154     Document Type: Article

References (22)

1. Coppi A, Natarajan R, Pradel G, et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J Exp Med 2011; 208:341-56.
2. Coppi A, Pinzon-Ortiz C, Hutter C, Sinnis P. The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med 2005; 201:27-33.
3. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989; 341:323-6.
4. Zavala F, Tam JP, Barr PJ, et al. Synthetic peptide vaccine confers protection against murine malaria. J Exp Med 1987; 166:1591-6.
5. Agnandji ST, Lell B, Fernandes JF, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012; 367:2284-95.
6. Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011; 365:1863-75.
7. Asante KP, Abdulla S, Agnandji S, et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-onimmunisation vaccines: 19 month follow-up of a randomised, openlabel, phase 2 trial. Lancet Infect Dis 2011; 11:741-9.
8. Guinovart C, Aponte JJ, Sacarlal J, et al. Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLOS One 2009; 4:e5165.
9. Olotu A, Moris P, Mwacharo J, et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PLOS One 2011; 6:e25786.
10. Rathore D, Sacci JB, de la Vega P, McCutchan TF. Binding and invasion of liver cells by Plasmodium falciparum sporozoites. Essential involvement of the amino terminus of circumsporozoite protein. J Biol Chem 2002; 277:7092-8.
11. Persson C, Oliveira GA, Sultan AA, Bhanot P, Nussenzweig V, Nardin E. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J Immunol 2002; 169:6681-5.
12. Noe AR, Espinosa D, Li X, et al. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate. PLOS One 2014; 9: e107764.
13. Cockburn IA, Tse SW, Radtke AJ, et al. Dendritic cells and hepatocytes use distinct pathways to process protective antigen from Plasmodium in vivo. PLOS Pathog 2011; 7:e1001318.
14. Ménard R, Janse C. Gene targeting in malaria parasites. Methods 1997; 13:148-57.
15. Espinosa DA, Yadava A, Angov E, Maurizio PL, Ockenhouse CF, Zavala F. Development of a chimeric plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy. Infect Immun 2013; 81:2882-7.
16. Brunã-Romero O, Hafalla JCR, González-Aseguinolaza G, Sano GI, Tsuji M, Zavala F. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int J Parasitol 2001; 31:1499-502.
17. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 1980; 207:71-3.
18. Zavala F, Tam JP, Hollingdale MR, et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 1985; 228:1436-40.
19. Roggero MA, Filippi B, Church P, et al. Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N-and C-terminal regions of the Plasmodium falciparum CS protein. Mol Immunol 1995; 32:1301-9.
20. Bongfen SE, Ntsama PM, Offner S, et al. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 2009; 27:328-35.
21. Rathore D, Nagarkatti R, Jani D, et al. An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J Biol Chem 2005; 280:20524-9.
22. Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009; 200: 337-46.